United BioSource (Suisse)
United BioSource (Suisse) is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 2 Open-Label, Multicenter Clinical Study of The Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Sponsor Inventiva
- Start (EU)
- Latest update
- Estimated end
(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor Arcus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
OPEN-LABEL SAFETY STUDY OF A 1-YEAR 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION
Sponsor Vanda Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Sponsor Springworks Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
(Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for United BioSource (Suisse)?
The 2026-10-09 snapshot links United BioSource (Suisse) to 8 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Safety Database. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for United BioSource (Suisse)?
The most frequently recorded therapeutic areas are Gastroenterology, Hepatology, Haematological Malignancies, Immunology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to United BioSource (Suisse) conducted?
The linked trials record locations in 18 countries, including Spain, France, Germany, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where United BioSource (Suisse) delivered services.
What can this page tell me about United BioSource (Suisse)'s trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under United BioSource (Suisse). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- United BioSource (Suisse) S.A.
- United BioSource (Suisse) SA
- United Biosource (Suisse) S.A.